MARKET COMPOSITE
BNTX - BioNTech SE8:00:00 PM 3/28/2024
Price
$92.25
-0.72 (-0.77%)
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is involved in developing FixVac product candidates, including BNT111, which is in Phase I clinical trial for advance melanoma; BNT112 that is in Phase I/II trial for prostate cancer; BNT113, which is in Phase I trial to treat HPV+ head and neck cancers; BNT114 that is in Phase I clinical trial for triple negative breast cancer; BNT115 in a Phase I trial in ovarian cancer; and BNT116, which is in preclinical trail for non-small cell lung cancer. It also develops neo-antigen specific immunotherapies, such as RO7198457, which is in Phase II clinical trial for first-line melanoma, as well as in Phase I clinical trial to treat multiple solid tumors; mRNA intratumoral immunotherapy comprising SAR441000 that is in Phase I clinical trial for solid tumors; and BNT141 and BNT142 to treat multiple solid tumors. In addition, the company develops RiboCytokines, which include BNT151, BNT152, and BNT152 for multiple solid tumors; chimeric antigen receptor T cell immunotherapies, such as BNT211 to treat multiple solid tumors, and BNT212 for pancreatic and other cancers; and checkpoint immunomodulators consisting of GEN1046 and GEN1042, which are in Phase I/II a clinical trial to treat multiple solid tumors. Further, it develops MVT-5873, an IgG1 monoclonal antibody, which is in Phase I/II clinical trial for pancreatic cancer; BNT411, small molecule immunomodulator product candidate for solid tumors; and infectious disease immunotherapies and rare disease protein replacement therapies. The company has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Genevant Sciences GmbH; Eli Lilly and Company; Bayer AG; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd.; Regeneron Pharmaceuticals, Inc.; and InstaDeep Ltd. The company was founded in 2008 and is headquartered in Mainz, Germany.
Stock Chart

Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from 

Finra

Moving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.

Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.

Stock news

    This biotechnology company has nearly 90% of its market value in cash and investments but is being shunned by investors even as they gravitate to the sector this year. The company is BioNTech (Ticker BNTX). It partnered with Pfizer to produce the leading Covid vaccine, Comirnaty, whose original messenger RNA technology was developed by BioNTech.

    BioNTech said on Monday the U.S. National Institutes of Health has sent a notice to the German company regarding default on the payment of royalties and other amounts related to its COVID-19 vaccine. BioNTech, which partnered with U.S. pharma giant Pfizer for its COVID-19 vaccine, however, said it disagreed with the positions being taken by the NIH and intends to defend against all allegations of breach. Spokespersons for the U.S. NIH did not immediately respond to Reuters' request for a comme...

    BioNTech ( NASDAQ:BNTX ) Full Year 2023 Results Key Financial Results Revenue: €3.82b (down 78% from FY 2022). Net...

    BioNTech SE ( NASDAQ:BNTX ) just released its latest annual report and things are not looking great. BioNTech missed...

    BioNTech SE (NASDAQ:BNTX) Q4 2023 Earnings Call Transcript March 20, 2024 BioNTech SE misses on earnings expectations. Reported EPS is $1.9 EPS, expectations were $2.64. BNTX isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Welcome to the BioNTech’s Fourth Quarter […]

    Q4 2023 BioNTech SE Earnings Call03-21-2024 05:43:14 AM

    Q4 2023 BioNTech SE Earnings Call

    BioNTech stock tumbled Wednesday after the Covid vaccine maker reported light fourth-quarter sales and profit.

    BioNTech SE (NASDAQ: BNTX) is way past its glorious Covid-19 days, when it thrived with Pfizer Inc (NYSE: PFE) for saving the world from the pandemic with their jointly developed vaccine. On Wednesday, BioNTech reported a revenue and earnings drop as it continues its shift towards cancer drug development, much like its peer Pfizer who also turned to oncology in response to falling sales. In January, Pfizer revealed that sales of the COVID shot plummeted 54% to $5.36 billion. Upon its latest repo

    BNTX earnings call for the period ending December 31, 2023.

    BioNTech estimates that its 10 most advanced cancer treatment candidates could generate combined peak sales of more than 10 billion euros ($10.9 billion), after reporting an ongoing decline in its COVID-19 vaccine business. "The peak sales estimate for that collection of assets is actually well over 10 billion euros in our long term estimates," BioNTech's head of strategy, Ryan Richardson, said in analyst call on Wednesday after the release of 2023 results. He would not be drawn on a combined ...